Navigation Links
Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Date:10/15/2007

ng statements relating to Lexicon's clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
3. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Colo. , Aug. 22, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... iCare,s third international medical cannabis conference taking place ... Strasbourg, France , on October 22, 2014.  ... other stakeholders, such as researchers, health professionals, and ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... , Aug. 21, 2014  Aptuit LLC ... West Lafayette, Indiana , has enhanced its ... characterization of small and large molecules, including biologic ... the Bruker maXisPlus Q-TOF mass spectrometer. ... , CEO, Aptuit, said, "The expanded large molecule ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... SYDNEY, May 23, 2011 Starpharma Holdings Limited (ASX: ... major phase 2 clinical study that demonstrated efficacy of ... Key Points: VivaGel(R) ... BV VivaGel(R) expected to avoid many shortcomings of ...
... Mass., May 20, 2011 Philips ... Philips FilterLine H Set and VitaLine H Set ... November 2010 through March 2011.ProductProduct DescriptionProduct Lot CodesM1923A ... M8330M10M8386N10M8411P10M8451P10M8477A11M8514A11M8572B11989803159581 , Philips Vitaline H Set Infant/Neo ...
Cached Medicine Technology:VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 2VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 3VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 4VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 5Recall of Infant and Neonatal-Sized FilterLine H Set and VitaLine H Set Sampling Lines 2
(Date:8/22/2014)... A national leader in home delivery of medical ... to grow. , Headquarters for the provider of sterile-use catheters ... at 8516 N.W. Expressway in Oklahoma City. , Rapid ... best places to work by OKCBiz magazine – demanded more ... in the past two years, and staff count grew 30 ...
(Date:8/22/2014)... 22, 2014 Menstrual leaks risk stains ... Sunrise, Fla., decided that there needed to be a ... use and producible in design variations, the Safety Net ... leaks, which avoids embarrassment and promotes peace of mind. ... pads. , The original design was submitted to the ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Counseling may ... a large-scale review finds. Researchers analyzed 66 studies ... of whom were at high risk for drinking problems. ... session, while participants in the rest of the studies ... individual sessions. A counseling technique called motivational interviewing ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- College can be a ... of things they can do to make the most of ... time to adjust, explore, meet new people and learn to ... of student wellness and assessment at St. John,s University in ... "Not all learning takes place in the classroom. College is ...
(Date:8/22/2014)... TORONTO, Aug. 22, 2014 Women with severe disabilities ... less often than women with no disabilities or no ... are also screened less often than women with moderate ... to Dr. Sara Guilcher, an affiliate scientist with the ... , Dr. Guilcher said women with disabilities often have ...
Breaking Medicine News(10 mins):Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:College Prep 101 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2
... greater bronchial responsiveness (BR) in people with certain common ... to cats. This suggests that reduced exposure to cats ... specific allergies. ,This was an unexpected finding, ... We presupposed that we would find increased responsiveness only ...
... dice and hope they come up seven: on Saturday thousands of ... the lucky number holds the key to marital bliss. ... to get married on Saturday, July 7, 2007 -- 7/7/7 -- ... ,In small chapels that have hosted weddings for decades and at ...
... influenza virus has been a pursuit of both historical and ... devastating single disease outbreak in modern history, and examining the ... prevent, future pandemics. ,When the complete sequence ... a watershed event for influenza researchers worldwide. ,In ...
... research from British Columbia found that aboriginal people who ... to use methadone maintenance therapy for treatment of ... colleagues evaluated factors associated with use of methadone maintenance ... to November 2005. At enrolment, 12.4% of Aboriginal participants ...
... Albert Einstein College of Medicine of Yeshiva University concluded ... likely to suffer from migraine headaches than teens from ... the July 3rd issue of Neurology, suggest that factors ... access to medical care, for example increase the prevalence ...
... Glasgow University and Baylor College of Medicine uncover 2 ... into the development of this potentially lethal disease. ... nonmelanoma skin cancer, which is the most common type ... in the USA each year. ,Mutations in ...
Cached Medicine News:Health News:Cat Exposure Increases Bronchial Responsiveness 2Health News:Will Seven Be the Lucky Number for Las Vegas Newlyweds? 2Health News:Influenza Virus Samples of 1918 2Health News:Low Income Family Adolescents Suffer Migraine 2Health News:Skin Cancer can Be Triggered by P53 Mutation 2
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: